

Vedat Hamuryudan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/777693/publications.pdf>

Version: 2024-02-01

162
papers

6,862
citations

71102

41
h-index

62596

80
g-index

163
all docs

163
docs citations

163
times ranked

5110
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behçet's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 448-450.	0.9	1
2	Safety of SARS-CoV-2 vaccination in patients with Behçet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine. <i>Rheumatology International</i> , 2022, 42, 973-987.	3.0	16
3	Emergence of new manifestations during infliximab treatment in Behçet's syndrome. <i>Rheumatology</i> , 2022, 61, 3746-3753.	1.9	5
4	Frequency of AA amyloidosis has decreased in Behçet's syndrome: a retrospective study with long-term follow-up and a systematic review. <i>Rheumatology</i> , 2022, 62, 9-18.	1.9	2
5	Aortic involvement in relapsing polychondritis: case-based review. <i>Rheumatology International</i> , 2021, 41, 827-837.	3.0	11
6	Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. <i>Rheumatology International</i> , 2021, 41, 1105-1114.	3.0	96
7	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 651715.	4.8	15
8	Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. <i>Rheumatology International</i> , 2021, 41, 1429-1440.	3.0	71
9	Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates. <i>Rheumatology International</i> , 2021, , 1.	3.0	3
10	The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome. <i>Rheumatology International</i> , 2021, , 1.	3.0	8
11	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 132, 3-13.	0.8	1
12	One year in review 2021: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-13.	0.8	17
13	Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. <i>Rheumatology</i> , 2020, 59, 799-806.	1.9	27
14	Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide. <i>Rheumatology</i> , 2020, 59, 2264-2271.	1.9	21
15	Characteristics and outcomes of Behçet's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients. <i>Internal and Emergency Medicine</i> , 2020, 15, 1567-1571.	2.0	22
16	Updated approach for the management of osteoporosis in Turkey: a consensus report. <i>Archives of Osteoporosis</i> , 2020, 15, 137.	2.4	12
17	Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study. <i>Frontiers in Immunology</i> , 2020, 11, 618973.	4.8	5
18	The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. <i>Rheumatology International</i> , 2020, 40, 1229-1238.	3.0	68

#	ARTICLE	IF	CITATIONS
19	Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: reply. <i>Rheumatology</i> , 2020, 59, 914-915.	1.9	0
20	Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey. <i>Rheumatology International</i> , 2020, 40, 1037-1044.	3.0	1
21	Vascular and Cardiac Involvement. , 2020, , 83-103.		2
22	Disease Management. , 2020, , 279-305.		1
23	Investigation of clinical profile of Behçet's syndrome-related versus idiopathic branch retinal vein occlusion. <i>Indian Journal of Ophthalmology</i> , 2020, 68, 1876.	1.1	1
24	Mortality in rheumatoid arthritis patients. <i>Ulusal Romatoloji Dergisi</i> , 2020, 12, 57-63.	0.0	0
25	One year in review 2020: Behçet's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 3-10.	0.8	6
26	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 752-762.	3.4	56
27	240. Factors ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	0
28	Update on the treatment of Behçet's syndrome. <i>Internal and Emergency Medicine</i> , 2019, 14, 661-675.	2.0	39
29	Secukinumab induced Behçet's syndrome: a report of two cases. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz041.	0.4	26
30	299. AORTIC INVOLVEMENT IN RELAPSING POLYCHONDITIS: A SYSTEMATIC REVIEW. <i>Rheumatology</i> , 2019, 58, 1.9		2
31	FRI0321 PERFORMANCE OF DIFFERENT PULMONARY HYPERTENSION SCREENING ALGORITHMS IN PATIENTS WITH SYSTEMIC SCLEROSIS PATIENTS. , 2019, , .		0
32	THU0298 INITIAL MANIFESTATIONS AND OUTCOME OF PATIENTS WITH INCOMPLETE BEHÇET'S SYNDROME. , 2019, , .		0
33	FRI0279 MYCOPHENOLATE MOFETIL IN THE TREATMENT OF MAJOR ORGAN INVOLVEMENT OF PATIENTS WITH BEHÇET'S SYNDROME. , 2019, , .		0
34	SAT0223 FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS. , 2019, , .		1
35	FRI0592 CLINICAL CHARACTERISTICS OF OLDER AGE-ONSET BEHÇET SYNDROME PATIENTS. , 2019, , .		0
36	THU0575 HYPERCOAGULABILITY AS A CAUSE OF THROMBOSIS IN BEHÇET'S SYNDROME: A SYSTEMATIC REVIEW AND META ANALYSIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	AB0241â€¦DISEASE COURSE AND COSTS OF A COHORT OF RHEUMATOID ARTHRITIS PATIENTS OVER A PERIOD OF 6 YEARS. , 2019, , .		0
38	Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study. Clinical and Experimental Rheumatology, 2019, 37 Suppl 122, 8.	0.8	1
39	One year in review 2019: Behçet's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 3-17.	0.8	12
40	Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies. Rheumatology International, 2018, 38, 607-622.	3.0	12
41	Surgical Treatment of Pulmonary Complications in Behçet's Syndrome. Seminars in Thoracic and Cardiovascular Surgery, 2018, 30, 369-378.	0.6	16
42	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. Rheumatology, 2018, 57, 2200-2212.	1.9	89
43	FRI0477â€¦Immunogenicity of infliximab among patients with behcet's syndrome: a controlled study. , 2018, , .		1
44	AB0703â€¦Long term follow-up of behçet's syndrome patients treated with cyclophosphamide. , 2018, , .		1
45	SAT0538â€¦Aortic involvement in relapsing polychondritis: a systematic review. , 2018, , .		0
46	THU0464â€¦Increased frequency of obstructive sleep apnea syndrome in behcet's syndrome patients with vena cava superior thrombosis. , 2018, , .		1
47	SAT0610â€¦A declining trend in frequency of secondary amyloidosis in behçet's syndrome. , 2018, , .		0
48	FRI0519â€¦Work productivity is impaired in patients with behçet's syndrome. , 2018, , .		1
49	SAT0546â€¦Sensorineural hearing loss in takayasu's arteritis. , 2018, , .		0
50	AB0764â€¦Comparison of disease characteristics in patients with juvenile-onset and adult-onset progressive systemic sclerosis. , 2018, , .		0
51	Current Surgical Treatment Options of Rheumatoid Shoulder. Current Rheumatology Reviews, 2018, 14, 200-212.	0.8	3
52	One year in review 2018: Behçet's syndrome. Clinical and Experimental Rheumatology, 2018, 36, 13-27.	0.8	9
53	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1750-1753.	2.0	25
54	THU0317â€¦Cardiovascular risk factors and comorbid diseases in takayasu arteritis. , 2017, , .		1

#	ARTICLE	IF	CITATIONS
55	FRI0307â€¦An outcome survey of 100 patients with cerebral venous sinus thrombosis due to behçet's syndrome followed up at a single, dedicated center. , 2017, , .		0
56	Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet Journal of Rare Diseases, 2017, 12, 105.	2.7	41
57	MiRNA and mRNA Profiling in Systemic Lupus Reveals a Novel Set of Cytokine - Related miRNAs and their Target Genes in Cases With and Without Renal Involvement. Kidney and Blood Pressure Research, 2017, 42, 1322-1337.	2.0	11
58	AB0558â€¦Biosimilar infliximab for behçet's syndrome. , 2017, , .		1
59	AB0394â€¦Tapering tnf inhibitors in rheumatoid arthritis: a retrospective study. , 2017, , .		0
60	FRI0348â€¦Associated inflammatory syndromes in takayasu's arteritis: many faces of a disease. , 2017, , .		0
61	Behçet's syndrome: providing integrated care. Journal of Multidisciplinary Healthcare, 2017, Volume 10, 309-319.	2.7	39
62	One year in review 2017: Behçet's syndrome. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 3-15.	0.8	11
63	Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation. Clinical and Experimental Rheumatology, 2017, 35 Suppl 108, 86-89.	0.8	9
64	FRI0372â€¦Rituximab for ANCA Associated Vasculitis Refractory To Conventional Treatment: A Retrospective Study on 25 Patients. Annals of the Rheumatic Diseases, 2016, 75, 569.2-569.	0.9	1
65	SAT0367â€¦Can We Differentiate Takayasu Arteritis from Atherosclerosis Using Carotid and Femoral Artery Doppler USG?: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 799.3-800.	0.9	0
66	Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet's Syndrome. Medicine (United States), 2016, 95, e3348.	1.0	69
67	Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy. Rheumatology International, 2016, 36, 1719-1725.	3.0	20
68	Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e258.	6.0	55
69	AB0573â€¦The Disease Associations of Takayasu's Arteritis. Annals of the Rheumatic Diseases, 2016, 75, 1100.2-1101.	0.9	0
70	Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey. Clinical and Experimental Rheumatology, 2016, 34, 1033-1037.	0.8	4
71	Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behçet's syndrome patients with pulmonary artery involvement during follow-up. Clinical and Experimental Rheumatology, 2016, 34, 92-96.	0.8	13
72	One year in review 2016: Behçet's syndrome. Clinical and Experimental Rheumatology, 2016, 34, 10-22.	0.8	16

#	ARTICLE	IF	CITATIONS
73	FRI0140â€¦Restarting Biologics in Patients Who Developed Tuberculosis During Anti TNF-Alpha Treatment. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 472.1-472.	0.9	1
74	THU0284â€¦Work Disability Over Time in Behçset's Syndrome Patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 298.4-299.	0.9	0
75	SAT0140â€¦How Correct are the Assumptions Made During the Development of Tuberculosis Screening Algorithms Before TNF-Alpha Antagonists?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 702.1-702.	0.9	0
76	AB0435â€¦Malignancies in Rheumatoid Arthritis Patients Treated with TNF-Alpha Antagonists. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1040.2-1040.	0.9	0
77	THU0300â€¦Bronchial Artery Enlargement May be the Cause of Recurring Hemoptysis in Behçset's Syndrome Patients with Pulmonary Artery Involvement Despite Treatment Response. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 304.2-304.	0.9	0
78	Pulmonary artery involvement in Behçset's syndrome: Effects of anti-Tnf treatment. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 369-373.	3.4	64
79	Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey. <i>Rheumatology International</i> , 2015, 35, 1473-1478.	3.0	12
80	Factors Affecting the Tuberculosis Risk in Patients Receiving Anti-Tumor Necrosis Factor-Î± Treatment. <i>Respiration</i> , 2015, 90, 191-198.	2.6	28
81	An outcome survey of 43 patients with Buddâ€“Chiari syndrome due to Behçsetâ€™s syndrome followed up at a single, dedicated center. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 602-609.	3.4	59
82	Behçset syndrome. , 2015, , 1328-1333.		1
83	Tuberculosis in patients receiving treatment of TNF-alpha inhibitors. , 2015, , .		0
84	Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFÎ±-inhibitor treatment. , 2015, , .		0
85	Suicidal ideation among patients with Behçset's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S30-5.	0.8	6
86	Behçset's syndrome: a critical digest of the 2014-2015 literature. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S3-14.	0.8	63
87	AB0602â€¦Anti-TNF Treatment for Refractory Vascular Involvement of Behçset's Syndrome: A Report of 16 Patients. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1005.1-1005.	0.9	1
88	Colchicine in Behçset Syndrome: A Longterm Survey of Patients in a Controlled Trial. <i>Journal of Rheumatology</i> , 2014, 41, 735-738.	2.0	17
89	Recovery from hypoxia and hypercapnic hypoxia: Impacts on the transcription of key antioxidants in the shrimp <i>Litopenaeus vannamei</i> . <i>Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology</i> , 2014, 170, 43-49.	1.6	16
90	Outcome Measures Used in Clinical Trials for Behçset Syndrome: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 599-612.	2.0	54

#	ARTICLE	IF	CITATIONS
91	THU0381â€¦Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 313.3-313.	0.9	1
92	SAT0345â€¦Patient Perceptions, Attitudes and Concerns about Anti-TNF Drugs:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 717.2-717.	0.9	0
93	Acute phase response and oxidative stress status in familial Mediterranean fever (FMF). <i>Modern Rheumatology</i> , 2012, 22, 431-437.	1.8	21
94	Pulmonary Artery Involvement and Associated Lung Disease in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 35-48.	1.0	151
95	Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. <i>Journal of Vascular Surgery</i> , 2012, 55, 157-163.	1.1	78
96	PMS19 Indirect Costs Associated With Ankylosing Spondylitis in Turkey. <i>Value in Health</i> , 2012, 15, A442.	0.3	0
97	Acute phase response and oxidative stress status in familial Mediterranean fever (FMF). <i>Modern Rheumatology</i> , 2012, 22, 431-437.	1.8	14
98	The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 202-7.	0.8	9
99	PMS24 The Cost of Care of Rheumatoid Arthritis and Ankylosing Spondylitis Patients in Tertiary Care Rheumatology Units in Turkey. <i>Value in Health</i> , 2011, 14, A306.	0.3	0
100	The estimated pulmonary artery pressure can be elevated in Behçetâ€™s syndrome. <i>Respiratory Medicine</i> , 2011, 105, 1739-1747.	2.9	16
101	Dissemination and evaluation of the 3E initiative recommendations for use of methotrexate in rheumatic disorders: results of a study among 2233 rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 388-389.	0.9	6
102	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71
103	Behçet's syndrome. , 2011, , 1575-1581.e1.		1
104	Interferon therapy in rheumatic diseases: state-of-the-art 2010. <i>Current Opinion in Rheumatology</i> , 2010, 22, 278-283.	4.3	32
105	Analyses of functional IL10 and TNF-Î± genotypes in Behçetâ€™s syndrome. <i>Molecular Biology Reports</i> , 2010, 37, 3637-3641.	2.3	19
106	Prognosis of Behçet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. <i>Rheumatology</i> , 2010, 49, 173-177.	1.9	35
107	Medical Management of Behçetâ€™s Syndrome. , 2010, , 317-338.		3
108	Vascular Disease in Behçetâ€™s Syndrome. , 2010, , 115-133.		1

#	ARTICLE	IF	CITATIONS
109	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1086-1093.	0.9	404
110	NRAMP1 (SLC11A1) gene polymorphisms that correlate with autoimmune versus infectious disease susceptibility in tuberculosis and rheumatoid arthritis. <i>International Journal of Immunogenetics</i> , 2009, 36, 15-19.	1.8	40
111	Genetic susceptibility to Behçet's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients. <i>Rheumatology International</i> , 2009, 29, 787-791.	3.0	12
112	Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis. <i>Rheumatology International</i> , 2009, 29, 743-747.	3.0	55
113	Thalidomide has both anti-inflammatory and regulatory effects in Behçet's disease. <i>Clinical Rheumatology</i> , 2008, 27, 373-375.	2.2	31
114	Tumor necrosis factor-alpha and Interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2008, 27, 1243-1248.	2.2	38
115	Lipid, protein, DNA oxidation and antioxidant status in rheumatoid arthritis. <i>Clinical Biochemistry</i> , 2008, 41, 538-543.	1.9	140
116	Atherosclerosis in Behçet's Syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 38, 1-12.	3.4	76
117	Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. <i>Rheumatology</i> , 2008, 47, 355-361.	1.9	96
118	Comment on "Cardiac Behçet Disease Presenting as Aortic Valvulitis/Aortitis or Right Heart Inflammatory Mass: A Clinicopathologic Study of 12 Cases". <i>American Journal of Surgical Pathology</i> , 2008, 32, 1914-1915.	3.7	2
119	Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behçet's syndrome. <i>Rheumatology</i> , 2007, 46, 1213-1214.	1.9	56
120	Headache in Behçet's Syndrome. <i>Headache</i> , 2005, 45, 911-919.	3.9	76
121	Effects of interferon- γ treatment on serum IL-6, IL-8, TNF- α and soluble TNF- α receptors in Behçet's disease. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 75-76.	1.1	5
122	Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. <i>Journal of Rheumatology</i> , 2005, 32, 98-105.	2.0	220
123	Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren's syndrome: a case-control study. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 575-577.	0.9	30
124	Coronary atherosclerosis in Behçet's syndrome: a pilot study using electron-beam computed tomography. <i>British Journal of Rheumatology</i> , 2004, 43, 1448-1450.	2.3	18
125	Pulmonary artery aneurysms in Behçet syndrome. <i>American Journal of Medicine</i> , 2004, 117, 867-870.	1.5	224
126	Behçet syndrome. <i>Current Opinion in Rheumatology</i> , 2004, 16, 38-42.	4.3	160

#	ARTICLE	IF	CITATIONS
127	Enteroclysis findings of intestinal Behcet disease: a comparative study with Crohn disease. <i>Abdominal Imaging</i> , 2003, 28, 308-312.	2.0	52
128	The Long-Term Mortality and Morbidity of Behçet Syndrome. <i>Medicine (United States)</i> , 2003, 82, 60-76.	1.0	635
129	Superoxide Dismutase Activity and Glutathione System in Erythrocytes of Men with Behcet's Disease.. <i>Tohoku Journal of Experimental Medicine</i> , 2002, 198, 191-195.	1.2	5
130	Glomerulonephritis in Behçet's Disease: Report of Seven Cases and Review of the Literature. <i>Clinical Rheumatology</i> , 2002, 21, 14-18.	2.2	25
131	Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study. <i>Israel Medical Association Journal</i> , 2002, 4, 928-30.	0.1	56
132	Behçet disease. <i>Current Opinion in Rheumatology</i> , 2001, 13, 18-22.	4.3	86
133	Behçet's disease: diagnostic and prognostic aspects of neurological involvement. <i>Journal of Neurology</i> , 2001, 248, 95-103.	3.6	276
134	A double-blind trial of colchicine in Behçet's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 2686-2692.	6.7	358
135	A reappraisal of amyloidosis in Behcet's syndrome. <i>British Journal of Rheumatology</i> , 2001, 40, 212-215.	2.3	30
136	Intestinal permeability in Behcet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 65-66.	0.9	34
137	Papulopustular skin lesions are seen more frequently in patients with Behcet's syndrome who have arthritis: a controlled and masked study. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1074-1076.	0.9	81
138	A double-blind trial of colchicine in Behçet's syndrome. , 2001, 44, 2686.		2
139	Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome. <i>Rheumatology</i> , 1999, 38, 734-736.	1.9	64
140	Neutrophil chemotaxis in Behcet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 658-658.	0.9	15
141	A successful renal transplantation in Behcet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 719-719.	0.9	6
142	Behçet's syndrome. <i>Current Opinion in Rheumatology</i> , 1999, 11, 53-58.	4.3	68
143	Wound healing in Behçet's syndrome. <i>International Journal of Dermatology</i> , 1998, 37, 120-123.	1.0	21
144	Genetic anticipation in Behcet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 45-48.	0.9	81

#	ARTICLE	IF	CITATIONS
145	Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome. <i>Annals of Internal Medicine</i> , 1998, 128, 443.	3.9	397
146	Mucocutaneous Lesions in the Behcet Syndrome. <i>Annals of Internal Medicine</i> , 1998, 129, 836.	3.9	1
147	Management of aneurysms in Behçet's syndrome: An analysis of 24 patients. <i>Surgery</i> , 1997, 121, 150-156.	1.9	208
148	7 Other forms of vasculitis and pseudovasculitis. <i>Bailliere's Clinical Rheumatology</i> , 1997, 11, 335-355.	1.0	21
149	Azathioprine in Behçet's syndrome. Effects on long-term prognosis. <i>Arthritis and Rheumatism</i> , 1997, 40, 769-774.	6.7	267
150	Topical cyclosporine A for treatment of oral ulcers of Behcet's syndrome. <i>International Journal of Dermatology</i> , 1997, 36, 720-720.	1.0	24
151	Surgical therapy of pulmonary arterial aneurysms in Behçet's syndrome. <i>Annals of Thoracic Surgery</i> , 1996, 61, 733-735.	1.3	53
152	The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): A masked and controlled study. <i>Clinical Rheumatology</i> , 1996, 15, 491-494.	2.2	23
153	Calciophylaxis: A condition mimicking necrotizing vasculitis. <i>Clinical Rheumatology</i> , 1996, 15, 498-500.	2.2	18
154	EPIDEMIOLOGY OF BEHÇET'S SYNDROME IN TURKEY. <i>International Journal of Dermatology</i> , 1996, 35, 618-620.	1.0	34
155	Gastrointestinal involvement in Behcet's syndrome: a controlled study.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 208-210.	0.9	152
156	Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease. <i>Clinical Rheumatology</i> , 1995, 14, 55-61.	2.2	64
157	Behçet's Syndrome. <i>BioDrugs</i> , 1995, 3, 102-107.	0.7	13
158	Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial.. <i>British Journal of Ophthalmology</i> , 1992, 76, 241-243.	3.9	184
159	Monozygotic twins concordant for behcet's syndrome. <i>Arthritis and Rheumatism</i> , 1991, 34, 1071-1072.	6.7	23
160	Amyloidosis in behçet's syndrome. <i>Arthritis and Rheumatism</i> , 1990, 33, 1586-1589.	6.7	21
161	Anti-Yersinia antibodies in patients with Behçet's disease. <i>Arthritis and Rheumatism</i> , 1989, 32, 1494-1495.	6.7	1
162	Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behçet's syndrome. <i>Rheumatology International</i> , 0, , .	3.0	2